The ROE as of November 2024 (TTM) for Genscript Biotech Corporation (GNNSF) is -13.66%

According to Genscript Biotech Corporation’s latest financial reports and current stock price. The company's current ROE is -13.66%. This represents a change of 273.74% compared to the average of -3.65% of the last 4 quarters.

Genscript Biotech Corporation (GNNSF) Historical ROE (quarterly & annually)

How has GNNSF ROE performed in the past?

The mean historical ROE of Genscript Biotech Corporation over the last ten years is -6.40%. The current -13.66% ROE has changed 113.35% with respect to the historical average. Over the past ten years (40 quarters), GNNSF's ROE was at its highest in in the March 2015 quarter at 4.16%. The ROE was at its lowest in in the December 2021 quarter at -29.13%.

Genscript Biotech Corporation (GNNSF) ROE by Quarter and Year

Discovering the peaks and valleys of Genscript Biotech Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genscript Biotech Corporation (GNNSF) Average ROE

How has GNNSF ROE performed in the past?

The current ROE of Genscript Biotech Corporation (GNNSF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Genscript Biotech Corporation (GNNSF) ROE vs. Peers

How is GNNSF’s ROE compared to its peers?

Genscript Biotech Corporation’s ROE is less than Telix Pharmaceuticals Limited (26.71%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Zentalis Pharmaceuticals, Inc. (-44.23%), greater than Innovent Biologics, Inc. (-2.16%), less than Oxford Nanopore Technologies plc (0%), greater than Nuvalent, Inc. (-43.29%), greater than Crinetics Pharmaceuticals, Inc. (-28.83%), greater than Inhibrx Biosciences, Inc. (-62.63%), less than Merus N.V. (1.62%), greater than Lyell Immunopharma, Inc. (-45.38%), greater than Kronos Bio, Inc. (-33.35%), greater than AgeX Therapeutics, Inc. (-68.82%), less than Lineage Cell Therapeutics, Inc. (172.71%), greater than Cadrenal Therapeutics, Inc. Common Stock (-35.54%), greater than ImmuCell Corporation (-93.71%), greater than Neoleukin Therapeutics, Inc. (-16.35%), greater than Nuvation Bio Inc. (-47.64%), greater than Ovid Therapeutics Inc. (-98.79%), greater than NextCure, Inc. (-33.40%), greater than Connect Biopharma Holdings Limited (-57.63%), less than null (7.21%),

Build a custom stock screener for Genscript Biotech Corporation (GNNSF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genscript Biotech Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genscript Biotech Corporation (GNNSF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genscript Biotech Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.